aol.comSEP 152 min read$MRNA

Flu season is coming: What to know about new vaccine, when to get your shot

Flu season is approaching, with the CDC noting low activity currently. The 2026-2027 flu season is expected to peak in winter, with 32 million illnesses and 24,000 deaths reported last season. The FDA approved Moderna's mRNA flu vaccine, mFLUSIVA, for adults 50+. Experts recommend flu shots between September and October, with side effects similar to other vaccines.

Original reporting

aol.com

Published Sep 15, 2026, 10:15 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 15, 2026, 10:27 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Flu season is coming: What to know about new vaccine, when to get your shot — source image — Source · aol.com

Decision brief

The 30-second read

$MRNABullishHigh

Why it matters

Moderna's new mRNA flu vaccine adds a novel product to its portfolio, potentially expanding market share.

Market read

Regulatory approval of a new flu vaccine is a material event for Moderna and may influence biotech sentiment.

What to watch

Potential pricing pressure and manufacturing scale constraints.

Relevance 8/10Novelty 9/10Timing: today

Background

Flu season approaches; CDC reports low activity but expects rise by December.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$MRNABullishHigh confidence

Context

FDA approved Moderna's new mRNA flu vaccine mFLUSIVA for adults 50+.

Expected impact

potential short-term upside as investors price in new product pipeline.

Evidence & confidence

Regulatory clearance is a material catalyst for a large biotech; market typically reacts positively.

Market effects

Sector

May spur broader biotech and vaccine sector optimism.

Regional

U.S. biotech market could see modest gains.

Global

Limited to investors tracking vaccine pipelines.

Counterpoint

What could challenge this read

Skeptics may question commercial uptake and competition from existing flu vaccines.

Key entities

Company
Moderna
Biotech firm developing mRNA therapeutics.
Regulator
FDA
U.S. Food and Drug Administration.

Read at source ← All news

SEP 15

$MRNAHighAI 8/10

2026 Covid vaccinations

The FDA approved updated Covid vaccines in late August. Moderna and Pfizer have shipped doses of the new shots, which are now available.

politicaldog101.com1 min

SEP 15

$MRNAHighAI 8/10

There ARE New Covid Vaccines Available this

The FDA approved updated Covid vaccines from Moderna, Pfizer, and Sanofi, which are now available. Eligibility includes those 65+ and younger individuals with high-risk conditions. Walgreens allows self-attestation, while CVS and Walmart have varying prescription requirements. Major medical groups recommend the vaccines for broader groups than the FDA's approval.

politicaldog101.com2 min

SEP 14

$MRKMed

New Cancer Vaccines Are on the Horizon. Disinformation Could Blunt Their Impact.

Anixa Biosciences, in partnership with the Cleveland Clinic, is developing a breast cancer vaccine that has shown positive early results in a clinical trial. Moderna and Merck's mRNA cancer vaccine, combined with an immunotherapy drug, succeeded in a late-stage trial for skin cancer. Doctors and researchers are concerned that vaccine misinformation could hinder the adoption of new cancer vaccines, citing the HPV vaccine as a cautionary tale. Some state lawmakers have also resisted HPV vaccine ma

truthout.org3 min

SEP 14

$MRNAHighAI 9/10

Moderna's COVID Vaccine Was a Historic Success. Could Its Cancer Vaccine Be Even Bigger?

Moderna (MRNA) shares rose 1.06% as its cancer vaccine, intismeran autogene, showed promising phase 3 results. The company collaborates with Merck (MRK) on the vaccine, which could target multiple cancer types. Analysts estimate potential revenue of $16.8B by 2035, though profits will be shared. Moderna's market cap is $57.4B, reflecting confidence in its pipeline, including the recently approved mFLUSIVA influenza vaccine.

fool.com3 min

SEP 12

$MRKMedAI 8/10

Is a New Treatment for Cancer on the Horizon? Moderna CEO Explains

Moderna and Merck's mRNA-based cancer vaccine showed promise in preventing melanoma recurrence. This marks the first use of mRNA technology in cancer treatment, according to Moderna's chairman.

nepm.org2 min